CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 249 enrolled
Drug / intervention
Docetaxel +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04001829
NCT04001829Phase 2Active

Prospective Validation Trial of Taxane Therapy (Docetaxel or Weekly Paclitaxel) and Risk of Chemotherapy-Induced Peripheral Neuropathy in African American Women

ECOG-ACRIN Cancer Research Group·interventional·Posted Jun 28, 2019·Updated May 15, 2026

In Brief

A Phase 2 clinical trial evaluating Docetaxel, Paclitaxel, and 2 other interventions for Anatomic Stage I Breast Cancer AJCC v8 and 20 related conditions. Active but no longer recruiting, targeting 249 participants across 485 sites.

Detailed Summary

This phase II trial studies whether a prior germline predictor of taxane-induced peripheral neuropathy (TIPN) can help identify a subgroup of patients who are at higher risk of chemotherapy-induced peripheral neuropathy in African American patients with stages I-III breast cancer. The study also investigates whether docetaxel maybe work better than paclitaxel with regard to TIPN rate/severity and dose reductions.

Study Details

Timeline

Phase 2Active
20202021202220232024202520262027
First PostedJun 28, 2019
Enrollment StartAug 9, 2019
Primary CompletionSep 19, 2023
Study CompletionMar 31, 2027
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 7.0 years ago

Interventions

Docetaxeldrug

Given IV

Paclitaxeldrug

Given IV

Quality-of-Life Assessmentother

Ancillary studies

Questionnaire Administrationother

Ancillary studies